Abstract
Aims:
To report the survival and event-free survival of children with acute lymphoblastic leukaemia treated in Auckland between 1985-1991, using an international protocol, ANZCCSG ALL Study V.
Methods:
The data were collected prospectively as part of the study. The analysis was carried out using standard survival methods.
Results:
At a median follow up of 7.5 years, the overall survival is 75% and event-free survival 60%.
Conclusions:
For an unselected series, these outcomes are comparable to overseas series. The survival for children diagnosed in the 1990's is likely to be similar.
MeSH terms
-
Adolescent
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asparaginase / administration & dosage
-
Child
-
Child, Preschool
-
Cranial Irradiation*
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Humans
-
Infant
-
Mercaptopurine / administration & dosage
-
Methotrexate / administration & dosage
-
New Zealand
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
-
Prednisone / administration & dosage
-
Proportional Hazards Models
-
Prospective Studies
-
Radiotherapy, Adjuvant
-
Survival Analysis
-
Treatment Outcome
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Vincristine
-
Cyclophosphamide
-
Mercaptopurine
-
Asparaginase
-
Prednisone
-
Methotrexate
-
Daunorubicin